Posted by Michael Wonder on 29 Jul 2019
Lonsurf (trifluridine/tipiracil) receives positive opinion from CHMP in the EU for patients with previously treated metastatic gastric cancer
26 July 2019 - Servier and its partner Taiho Pharmaceutical announced today that the CHMP of the EMA has issued a positive opinion for Lonsurf (trifluridine/tipiracil) as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastro-esophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
The marketing authorisation application was supported by data from the global Phase III trial TAGS (TAS-102 Gastric Study) which was a randomised, double-blind study evaluating Lonsurf, plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments.
